A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype by Tougaard, BG et al.
  “Tougaard B, et al.” Hereditary Apo A-1 amyloidosis with variable phenotype 
1 
 
A case report of hereditary apolipoprotein A-I amyloidosis associated with a 
novel APOA1 mutation and variable phenotype 
 
Birgitte G. Tougaard1, Katja Venborg Pedersen3, Søren Rasmus Palmelund Krag2, Janet A. 
Gilbertson4, Dorota Rowczenio4, Julian D. Gillmore4, Henrik Birn1, 
1Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark; 2Department 
of Pathology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Clinical 
Genetics, Aarhus University Hospital, Aarhus, Denmark; 4National Amyloidosis Centre, UCL 
Division of Medicine, Royal Free Hospital, London, United Kingdom. 
Key Words: Variable phenotype, Hereditary, Amyloidosis, Apolipoprotein A-I encoding mutation, 
APOA1. 
 
Correspondence to: 
Birgitte G. Tougaard, MD 
Department of Renal Medicine 
Aarhus University Hospital 
Brendstrupsgaardsvej 100 
DK-8200 Aarhus N, Denmark  
E-mail: bgtougaard@gmail.com 
  “Tougaard B, et al.” Hereditary Apo A-1 amyloidosis with variable phenotype 
2 
 
Abstract 
Apolipoprotein A-I (apoAI) amyloidosis is a non-AL, non-AA, and non-transthyretin type of 
amyloidosis associated with mutations in the APOA1 gene inherited in an autosomal dominant 
fashion. It is a form of systemic amyloidosis, but at presentation, can also mimic localized 
amyloidosis. The renal presentation generally involves interstitial and medullary deposition of apo 
A-I amyloid protein. We describe the identification of apo A-I amyloidosis by mass spectrometry in 
a 52-year old male, with no family history of amyloidosis, presenting with nephrotic syndrome and 
associated with heterozygosity for a novel APOA1 mutation (c.220T>A) which encodes the known 
amyloidogenic Trp50Arg variant. Renal amyloid deposits in this case were confined to the glomeruli 
alone, and the patient developed progressive renal impairment. One year after diagnosis, the patient 
had a successful kidney transplant from an unrelated donor. Pathogenic mutation in the APOA1 gene 
are generally associated with symptoms of amyloidosis. In this family however, genotyping of family 
members identified several unaffected carriers suggesting a variable disease penetrance, which has 
not been described before in this form of amyloidosis and has implications when counselling those 
with APOA1 mutations. 
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Introduction: 
Amyloidosis is characterized by extracellular deposition of insoluble protein and 
peptides.  Accumulation of amyloid in tissues, as well as oligomers of amyloid protein may cause 
organ damage, and if affecting the kidney, is often associated with progression to end stage renal 
disease. [Bergesio F, et al. 2008] 
Hereditary amyloidosis is caused by mutations in specific, protein encoding genes 
leading to misfolding and aggregation of the protein. Several proteins have been identified including 
fibrinogen A-α chain [Benson MD, 2003], transthyretin [Ando Y, et al. 2013], apolipoprotein A-I 
(apo A-I) [Obici L, et al. 2006], apolipoprotein A-II (apo-AII) [Yazaki M, et al, 2001], lysosome [DR 
Booth et. al 1969] and gelsolin. [Benson MD, 2003] 
Mutations in the APOA1 gene are associated with autosomal dominant inherited 
amyloidosis [Van Allen MW, Frohlich JA, Davis JR, 1969]. To date, 20 different amyloidogenic 
mutations in APOA1 are listed in the Human Genome Database (HGMD: 
http://www.hgmd.cf.ac.uk/ac/index.php; accessed on June 2015). The majority of these are 
missense/nonsense mutations but small deletions/insertions have also been reported. The APOA1 
gene mutations are associated with systemic amyloidosis, but can initially present as localized 
disease, particularly in the larynx and skin. Multiple organs including liver, kidneys, peripheral 
nerves, gastrointestinal tract, testes, spleen, heart, larynx, and skin may be involved. The clinical 
presentation varies from severe and progressive cardiac failure at the age of 20 and death in the late 
4th decade, to late onset disease presenting in the 5th decade with gradually progressing renal failure.  
Renal involvement is common and most often characterized by amyloid deposition in the medullary 
interstitium and/or vasculature.  In most cases of apoAI amyloidosis caused by APOA1 mutations, 
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there is a prior family history of similar disease (Table I) and so far, unaffected mutation carriers have 
not been described. [Erikson M et al, 2000] 
 
 Results: 
A 52-year old Danish male with no family history of renal disease presented with 
hypertension, renal insufficiency, and nephrotic syndrome. At presentation, he had an eGFR of 36 
ml/min/1,73m2 and proteinuria in the range of ~7 g/24 h. A kidney biopsy revealed amyloid with 
extensive glomerular involvement (Figure 1). Immunostaining for serum amyloid A protein (SAA), 
kappa and lambda immunoglobulin light chains and transthyretin were all negative. A bone marrow 
aspirate and trephine biopsy were normal without clonal plasma cells or amyloid. Nerve conduction 
studies were normal and cardiac investigations, including echocardiography and cardiac biomarkers 
did not suggest cardiac infiltration by amyloid. Proteomic analysis of microdissected amyloid 
deposits from a kidney biopsy revealed large amounts of apoAI, which scored as number one, in 
conjunction with the amyloid ‘signature’ proteins serum amyloid P component and apolipoprotein E 
(figure 1D). Simultaneously, specific staining of glomeruli with antibodies against apoAI (figure 1B) 
also confirmed the presence of apoAI protein.  Subsequent sequencing of APOA1 revealed 
heterozygosity for a mutation encoding the Trp50Arg variant, c.220T>A (cDNA reference sequence 
NM_000039.1).  No mutations in other amyloid genes were identified. Except for paresthesia, there 
were no symptoms of extra-renal involvement by amyloid.  Serum amyloid P component (SAP) 
scintigraphy revealed a large total body amyloid load with deposits in the liver, spleen, and kidneys 
(figure 1C). Despite treatment, including an angiotensin II receptor blocker and a statin, significant 
albuminuria persisted and kidney function declined to end-stage kidney disease within 10 months of 
diagnosis. Genetic analysis of the patient’s family identified the mother, two older brothers, and a 
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younger sister as mutation carriers but with no symptoms or signs of amyloidosis. The proband 
received a successful unrelated kidney transplant approximately 6 months later. 
 
Discussion: 
ApoAI amyloidosis in this case was suggested by immuhistochemistry and confirmed 
by mass spectrometry [Sethi S. et al. 2013] and genetic analysis.  An extensive work up showed no 
signs of monoclonal disease or inflammatory disease, supporting the pathogenicity of the glomerular 
apoAI amyloid deposits presenting with nephrotic syndrome and leading to end stage renal failure. 
In general, renal involvement in apoA1 amyloidosis is believed to be medullary/interstitial rather than 
glomerular. In this case, however, the amyloid deposits were identified only in the glomeruli reported 
only in three other cases. (Table I) 
A single case of an identical amino acid substitution due to a different, single nucleotide 
exchange (APOA1 c.220T>C) has previously been reported in a patient with a family history of 
amyloidosis. [Booth DR, et al. 1995]. The patient presented with symptoms of amyloidosis at age 35 
years and had widespread organ involvement, including liver, spleen, and gastrointestinal tract. Renal 
involvement was noted in a kidney biopsy; however, kidney function only slowly declined leading to 
a kidney transplantation 10 years after presentation. In the current case, a culprit APOA1 mutation 
was identified in several family members with no signs or symptoms of amyloidosis, including the 
patient’s mother at 80-years of age. Thus, the mutation and resulting amino acid substitution is 
associated with interfamilial and intrafamilial variability in disease penetrance.  It is not known 
whether this may be due to variable expression of the variant. The recognition of this variation in 
disease penetrance is important for the counselling of clinically unaffected family members with a 
similar genotype.  
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In conclusion, the current case demonstrates the successful identification of apoAI 
amyloidosis by proteomic analysis of amyloid deposits associated with a novel APOA1 mutation 
encoding a previously reported pathogenic apoAI variant. Genotyping of family members identified 
several unaffected older carriers indicating variable penetrance. The patient presented with nephrotic 
syndrome, which is unusual in this form of amyloidosis, and the renal biopsy showed isolated 
glomerular amyloid deposits that may mimic other types of amyloidosis.  
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